A reminder to join us for the inaugural Cognition in MS special interest group meeting 31st Jan.
https://t.co/WDWxjBD6YM
@IntNatlWiMS@dr_sarahamorrow@HannekeHulst @laurenstrober
Today the results of the MS-STAT2 trial were announced by Professor Jeremy Chataway at the ECTRIMS research conference in Copenhagen.
This trial tested simvastatin, commonly used to treat high cholesterol, in 964 people with secondary progressive MS. (1/6)
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial - PubMed https://t.co/VvO8N3b91b
New systematic review out with @dankajandric@AnishaDoshi@Mennoke@geoffjmparker and others showing that network connectivity changes in MS are cognitively relevant - but show both increases & decreases throughout the disease course https://t.co/A3xI2HllUi
Today I spoke about insights from functional imaging into plasticity versus maladaptation in #MultipleSclerosis. Great to be on-site again after all this time! A lot of bright young clinicians and scientists in this wonderful @ECTRIMS@imscogs summerschool on #cognition in #MS.
Fantastic to see so many of our students at UCL’s in-person graduation ceremonies!
Here’s @UCLBrainScience Faculty Dean Prof Alan Thompson celebrating with #UCLBrainiacs Rosa, Floriana, Sara & Anisha at one of today's ceremonies 🎓🎉
#UCLBrainiacsGrad#UCLGrad
In case you thought Prof. Chataway wasn’t working hard enough on MS-STAT2! Lots more hope for new treatments in progressive MS through the OCTOPUS study 🐙 🐙 🐙 �� #stopMS
https://t.co/4rcT9Tvmx2
Dear MS-STAT2 participants @UCLIoN : I’ve sent you all an email!
About time we had another zoom catch-up with the boss! Email me back and I’ll send you the invite link.
Prof. Chataway wants a cuppa tea and a chat to see how you’re all doing 🙌
I'm exhausted. Been helping to transfer intubated patients around the hospital and resuscitate deteriorating patients on the ward in conjunction with colleagues from ICU. But there are still urgent and emergency operations taking place. Its relentless... Our ICUs are overflowing.
Shocking national shortfall in staffing calculated by audit and data workstream of over 100 neurologists, 200 nurses and 100 coordinators... #RtB4MS2020
BREAKING NEWS | Siponimod, a new treatment for secondary progressive MS, has been approved for use on NHS Scotland.
It's the first oral treatment to be made available on the NHS in Scotland for secondary progressive MS.